Pinealon Dosage: Protocol, Chart, and What the Evidence Actually Shows | FormBlends

Trust Signals

Key Takeaways

• All human pinealon dosing data originates from one Russian research group (St. Petersburg Institute of Bioregulation and Gerontology); no independent RCT has confirmed an optimal human dose.
• The most commonly cited range is 5 to 20 mg per day for a 10-day cycle, delivered intranasally or orally, based on institutional protocols, not randomized controlled trial outcomes.
• Pinealon is the tetrapeptide Ala-Glu-Asp-Gly. Its short sequence means rapid enzymatic degradation in the gut, which is why intranasal delivery is the preferred route in source literature.
• No pharmacokinetic study in humans has measured pinealon plasma half-life, volume of distribution, or confirmed CNS penetration after any route of administration.
• Melatonin, a much better-studied compound for circadian and neuroprotective goals, has a decisive evidence advantage over pinealon at every evidence tier.

Direct Answer: What Is the Pinealon Dosage?

Pinealon dosage in the source literature ranges from roughly 5 to 20 mg per day given for 10-day courses, one to two times yearly, delivered intranasally or orally. No peer-reviewed RCT has established a confirmed optimal human dose. Every specific number in circulation traces to non-randomized institutional work from a single research group, not independent replication.

Table of Contents

What Is Pinealon and Why Does It Matter for Dosing?

Pinealon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (alanine-glutamic acid-aspartic acid-glycine). It was developed as part of the Soviet and post-Soviet bioregulatory peptide program led by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The peptide is described as a "cytamine" or peptide bioregulator targeting brain and pineal-related tissue.

Why does the structure matter for dosing decisions? Short peptides like this tetrapeptide face predictable pharmacokinetic challenges: proteolytic enzymes in the gut and bloodstream cleave peptide bonds rapidly. How you deliver the compound determines how much intact peptide reaches any intended target. Dosing numbers pulled from oral animal studies are not directly translatable to intranasal human protocols, yet they are routinely conflated on commodity pages.

Evidence Ledger: What Is the Evidence Behind Pinealon Claims?

Pinealon Peptide Dosage Chart

The figures below are drawn from the published institutional protocols and practitioner-reported adaptations. They represent what has been used, not what has been proven optimal in a controlled trial.

No weight-based human dosing table exists in peer-reviewed literature. Animal study doses are not reliably scalable to human equivalents without proper allometric conversion and human PK validation, neither of which has been published for pinealon.

Mechanism With Numbers: How Pinealon Is Proposed to Work

Pinealon's proposed mechanism centers on epigenetic gene regulation rather than receptor binding in the classical sense. The Khavinson group has published work suggesting that short peptides matching chromatin-binding motifs can interact with histone-DNA complexes and modulate transcription factor access to promoter regions.

Specifically, the research group's molecular modeling work proposes that Ala-Glu-Asp-Gly can form complementary contacts with gene promoter regions associated with antioxidant defense (including superoxide dismutase-related genes) and anti-apoptotic pathways in neural tissue. Published cell culture experiments from this group report changes in expression of multiple genes after peptide exposure, though independent replication of the specific gene expression claims in a separate laboratory is not documented in the literature available for review here.

What this mechanism does NOT prove: Even if the epigenetic interaction occurs in a dish, this does not confirm that intact pinealon reaches neural cell nuclei after intranasal dosing in a living human, that the gene expression changes translate to the clinical outcomes users seek, or that any effect lasts beyond the immediate course.

What Most Pages Get Wrong About Pinealon Dosage

This is the section commodity pages omit entirely.

1. Presenting animal mg/kg doses as human doses without conversion. When source literature describes weight-based dosing in rodents, this cannot be applied directly to humans. The FDA's standard allometric scaling uses a body surface area correction factor that places human equivalent doses well below the animal mg/kg figure, not equal to it. Commodity pages skip this and imply you should dose at the animal figure.

2. Treating "no reported adverse events" as a safety certification. Small, non-randomized studies from a single group have limited power to detect rare or delayed adverse events. Absence of a published safety signal is not the same as a confirmed safety profile.

3. Ignoring bioavailability of oral pinealon. Tetrapeptides face digestion by gastric pepsin and intestinal proteases. There is no published oral bioavailability figure for pinealon in humans. Oral dosing at the same mg number as intranasal dosing almost certainly delivers less intact peptide to any target tissue, yet protocols rarely distinguish between routes when quoting a dose number.

4. Conflating "pineal gland" in the name with "proven melatonin-like effect." The word pinealon implies pineal gland affinity, but the mechanism proposed is gene regulatory, not melatonin agonism. Listing it as a "melatonin alternative" overstates the evidence dramatically.

5. Purity reality. The research peptide market contains variable-quality pinealon. Sequence fidelity (confirming the exact Ala-Glu-Asp-Gly order, not just amino acid content) requires mass spectrometry. Many COAs on the market show only HPLC purity, which confirms the size of a peak but not the identity of the amino acid sequence. A tetrapeptide with the right molecular weight but wrong sequence order would pass an HPLC purity test and still be pharmacologically irrelevant.

Chemistry Behind the Rules: Why Route of Administration Changes Everything

The practical rule "use intranasal over oral for pinealon" exists because of two chemical realities.

Proteolytic degradation: Peptide bonds, the amide linkages between each amino acid in the Ala-Glu-Asp-Gly chain, are substrates for gastric pepsin (active at low pH, roughly 1.5 to 3.5) and for serine and metalloprotease enzymes throughout the small intestine. A four-amino-acid chain offers three peptide bonds as cleavage targets. The shorter the peptide, the faster complete hydrolysis occurs. This is not unique to pinealon; it is a fundamental challenge for all therapeutic peptides administered orally without encapsulation or enteric protection.

The olfactory route hypothesis: Intranasal delivery deposits material onto the olfactory epithelium in the upper nasal cavity. From there, compounds can travel along olfactory nerve axons through the cribriform plate and enter the olfactory bulb, which is CNS tissue. This bypass of the blood-brain barrier is well-documented for some small molecules and some nanoparticle formulations. Whether a free tetrapeptide of this sequence uses this route efficiently, and in what amounts, has not been measured with pharmacokinetic data in humans for pinealon specifically. The rationale is sound in principle; the confirmation for this molecule is absent.

Stability in solution: Aspartate (Asp) and glutamate (Glu) residues are vulnerable to deamidation and to oxidation under acidic or oxidizing conditions. This means a reconstituted pinealon solution left at room temperature, exposed to light, or stored in a low-pH buffer will lose potency over time through a predictable chemical degradation pathway, not just through microbial contamination. Store reconstituted peptide cold (2 to 8 degrees Celsius), shielded from light, and use within a period consistent with supplier stability data, if available. If no stability data is provided, treat open vials as short-lived.

Honest Head-to-Head: Pinealon vs. Melatonin and Epithalon

Conclusion: For any evidence-based circadian or neuroprotective goal, melatonin has a decisive advantage. Pinealon is an exploratory compound. Choosing pinealon over melatonin for a documented, clinical goal is not currently supported by comparative evidence.

Operational Guide: Reading a COA and Spotting a Degraded Product

What a minimum-acceptable COA for pinealon must contain:

• Peptide sequence confirmation by mass spectrometry (LC-MS or MALDI-TOF), not HPLC purity alone. Mass spectrometry confirms molecular weight consistent with Ala-Glu-Asp-Gly (calculated MW approximately 403.4 g/mol for the free acid form; verify against your supplier's specification).
• HPLC purity of 98% or greater at 220 nm detection.
• Endotoxin (LAL) test result with a clear pass threshold, especially relevant for any non-oral route.
• Residual solvent data if the peptide was synthesized using organic solvents (standard in solid-phase peptide synthesis).
• Lot number and date of manufacture so you can correlate to your specific vial.

Reconstitution notes: Pinealon is typically supplied as a lyophilized powder. Reconstitution is commonly performed with bacteriostatic water. For a 10 mg vial reconstituted with 1 mL bacteriostatic water, you get a 10 mg/mL solution. To deliver 5 mg, you draw 0.5 mL (50 units on a standard 100-unit insulin syringe). Always do the math from your specific vial concentration, since vial sizes vary by supplier.

Signs of degradation in solution:

• Solution that was clear at reconstitution becomes cloudy or develops visible particulate: indicates aggregation or contamination. Discard.
• Color shift toward yellow or brown: indicates oxidation of Glu or Asp residues or contamination. Discard.
• Precipitate that does not dissolve after gentle warming to room temperature: indicates irreversible aggregation. Discard.
• Odor change: any ammonia-like or sulfurous smell suggests degradation. Discard.

Lyophilized (dry, sealed) product is stable under proper conditions for longer periods than reconstituted solution. Once reconstituted, refrigerate and use within a timeframe consistent with your bacteriostatic water's preservative capacity and the supplier's recommendations. In the absence of specific supplier stability data, conservative practice treats open reconstituted vials as valid for no more than a few weeks refrigerated.

FAQ

What is the standard pinealon dosage per day?

Russian institutional research used weight-based dosing in animal studies, and human pilot work from the St. Petersburg Institute of Bioregulation explored intranasal and oral dosing in the range of roughly 5 to 20 mg per day for 10-day courses. No peer-reviewed RCT has established a confirmed optimal human dose.

What is the pinealon 20mg protocol?

The 20 mg daily figure circulates in Russian biogerontology literature as the upper end of a 10-day intranasal or oral course repeated one to two times per year. It is not validated by a controlled human trial and should be treated as an exploratory, not established, dose.

Is pinealon taken once a day or split into doses?

Available protocols from the originating research group describe once-daily administration. Because pinealon is a short tetrapeptide subject to rapid enzymatic clearance, some practitioners split into two daily doses, but no comparative data exists to confirm that splitting improves outcomes.

How long is a pinealon cycle?

The most commonly cited cycle from Russian research is 10 consecutive days, repeated up to twice yearly. Some protocols extend to 20 days. There is no human RCT data establishing optimal cycle length or washout period.

What route of administration is used for pinealon?

Pinealon has been studied intranasally and orally in Russian institutional work. Intranasal is preferred because the blood-brain barrier penetration challenge is partially bypassed via the olfactory route. Injectable use exists in practitioner communities but is off-label with no supporting human RCT data.

Does pinealon cross the blood-brain barrier?

In vitro and animal data suggest the tetrapeptide Ala-Glu-Asp-Gly can interact with epigenetic targets in brain tissue, and intranasal delivery is proposed to reach the CNS via olfactory pathways. Confirmed BBB transport in humans has not been directly measured in a published pharmacokinetic study.

What are the reported effects pinealon is dosed for?

Research from the originating group reports effects on oxidative stress markers, circadian rhythm support, neuroprotection in age-related models, and retinal cell survival. All documented effects come from animal studies or small, non-randomized human cohorts. No independent large RCT exists.

Can pinealon be stacked with other peptides?

Russian bioregulatory research often uses pinealon alongside Epithalon or other cytamins. No interaction or synergy data from controlled trials exists. Combining unvalidated compounds multiplies uncertainty about safety and pharmacokinetics.

What does pinealon degradation look like and when is a batch compromised?

Tetrapeptides degrade through oxidation of the aspartate and glutamate residues and hydrolysis of peptide bonds. Visible signs include cloudiness, color shift toward yellow or brown in solution, or precipitate that does not dissolve on gentle warming. Degraded product should be discarded.

Is pinealon FDA-approved?

No. Pinealon is not FDA-approved for any indication. It is available as a research compound. Use outside a supervised research setting is not supported by regulatory approval in the United States or the EU.

How does pinealon compare to melatonin for circadian support?

Melatonin has hundreds of RCTs, an established safety profile, regulatory approval for some indications, and clear pharmacokinetics. Pinealon has animal data and small non-randomized human studies. For evidence-based circadian support, melatonin currently has a decisive evidence advantage over pinealon.

What should I look for on a pinealon COA?

Look for sequence confirmation (Ala-Glu-Asp-Gly) by HPLC or mass spectrometry, purity above 98%, endotoxin testing result, and residual solvent data. A COA without mass spec confirmation cannot verify sequence fidelity.

Sources

1. Khavinson VKh, Bondarev IE, Butyugov AA. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. (Referenced for context on the Khavinson group's peptide bioregulator program; not a pinealon-specific RCT.)
2. Khavinson VKh. "Peptides and Ageing." Neuro Endocrinology Letters. 2002;23 Suppl 3:11-144. (Overview of the bioregulatory peptide program including cytamins and short peptides.)
3. Khavinson V, Diomede F, Mironova E, et al. "AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism." Molecules. 2020;25(3):609. PMC7037346. (Directly relevant; covers AEDG tetrapeptide epigenetic mechanism in neural tissue context.)
4. Rukshin I, Santos J, Bhatt S, et al. "Comparative Neuroprotective Effects of Different Routes of Administration of Cerebrolysin..." CNS Neuroscience and Therapeutics. 2016;22(10):809-817. (Cited for olfactory route pharmacology general context; not pinealon-specific.)
5. Illum L. "Nasal drug delivery: new developments and strategies." Drug Discovery Today. 2002;7(23):1184-1189. (Mechanism of intranasal CNS delivery via olfactory pathway.)
6. FDA Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. 2005. (Allometric scaling methodology referenced for species dose conversion discussion.)
7. Mahato RI, Narang AS. Pharmaceutical Dosage Forms and Drug Delivery. 2nd ed. CRC Press, 2012. (General peptide oral bioavailability and proteolysis context.)
8. Kvetnoy IM, Polyakova VO, Basharina OV, et al. Various publications on pineal peptide biology from the St. Petersburg Institute. (Cited generally; readers should search PubMed for "Khavinson pinealon" for the most current indexed output.)

Disclaimers

Platform: FormBlends is an informational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide compound.

Research Compound: Pinealon is sold as a research compound only. It is not approved by the FDA or EMA for human therapeutic use. It is intended for research purposes in jurisdictions where such use is legal.

Results: Individual results, if any, will vary. The outcome data discussed on this page comes from animal studies and small, non-randomized human observations. These results may not apply to you.

Trademark: All product names and trademarks mentioned belong to their respective owners. FormBlends has no affiliation with any manufacturer of pinealon or related peptides.

Related peptide guides

• Peptide therapy guide hub
• Peptide dosage and reconstitution calculator
• Epitalon Dosage: Protocols, Cycles & What the Evidence Actually Shows | FormBlends
• NAD 500 mg Dosage Guide: Injection Chart, Vial Sizes & Evidence | FormBlends
• DSIP Dosage: Complete Peptide Dosing Chart & Protocol | FormBlends
• FOXO4-DRI Dosage | FormBlends
• IGF-1 LR3 Dosage: Protocol, Timing & Evidence | FormBlends